首页 > 市场调查报告书 > 製药

癌症骨疾病

市场调查报告书

商品编码

1812547

骨癌药物市场：依药物类型、适应症、通路和地区划分

Bone Cancer Drugs Market, By Drug Type, By Disease Indication, By Distribution Channel, and By Region

出版日期: 2025年08月20日 | 出版商:

Coherent Market Insights | 英文 204 Pages | 商品交期: 2-3个工作天内

价格

简介目录

骨癌治疗市场规模预计在 2025 年达到 14.233 亿美元，预计到 2032 年将达到 20.296 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 5.2%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	14.233亿美元
效能数据	2020-2024	预测期	2025-2032
预测期：2025-2032年复合年增长率：	5.20%	2032年的价值预测	20.296亿美元

癌症是一种致命的慢性疾病，由于其高度侵袭性和长期疾病史而具有高死亡率。骨癌是一种在骨组织中不受控制地生长的癌症。骨癌市场按骨癌类型细分为：原发性骨癌和续发性骨癌。原发性骨癌是由于骨骼和相关组织快速且不受控制地生长而导致的癌症。另一方面，次发性骨癌是一种起源于身体其他部位并转移到骨骼的癌症。骨癌也分为骨癌、伊文氏肉瘤、软骨肉瘤、脊索瘤、纤维肉瘤和腺瘤。

市场动态

预计预测期内，越来越多的新药上市和监管部门核准的骨癌市场将会成长。例如，2020 年 5 月，百时美施贵宝和蓝鸟生物宣布，美国食品药物管理局(FDA) 拒绝了 2020 年 3 月提交的 idecabutadien bicleucel (idecel; bb2121) 用于治疗多次治疗后的復发和难治性多发性骨髓瘤的生技药品核准(BLA)。此外，2016 年 4 月，Advaxis, Inc. 的 Lm Technology 免疫疗法产品 ADXS-HER2接受了美国FDA 的快速通道认证，该产品针对 HER2 表达癌症，用于治疗可手术切除的骨癌。 FDA的快速通道认证将使该公司能够进一步加快其开发进程，为患者提供更快、更好的治疗。

本次调查的主要特点

本报告对全球骨癌药物市场进行了详细分析，并提供了预测期 2025-2032 的市场规模（百万美元）和年复合成长率（CAGR%），以 2024 年为基准年。
它还强调了各个领域的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球骨癌治疗市场的主要企业。
本报告的见解将使负责人和公司经营团队能够就未来的产品发布、最新策略、市场扩张和行销策略做出明智的决策。
全球骨癌治疗药物市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球骨癌治疗市场的各种策略矩阵更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 1,423.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.20%	2032 Value Projection:	USD 2,029.6 Mn

Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing's sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.

Market Dynamics

The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2020, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA's Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.

Key features of the study

This report provides in-depth analysis of the global bone cancer drug market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global bone cancer drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market.

Market Segmentation

By Drug Type Insights (Revenue, USD Mn, 2020 - 2032)
- Antimetabolites
- Anthracyclines
- Antibiotics
- Others (RANK ligand inhibitors, etc.)
By Disease Indication Insights (Revenue, USD Mn, 2020 - 2032)
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing's Sarcoma
By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Advaxis, Inc.
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co.
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Market Trends
Regulatory Scenario
New Product Launches/Approvals
Merger, Acquisition and Collaboration Scenario
PEST Analysis
PORTER's Analysis

4. Global Bone Cancer Drugs Market, By Drug Type, 2020- 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Anthracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Others (RANK ligand inhibitors, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)

5. Global Bone Cancer Drugs Market, By Disease Indication, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)
Osteosarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)
Chondrosarcoma
- Introduction
Ewing's Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)

6. Global Bone Cancer Drugs Market, By Distribution Channel, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020- 2032, (USD Mn)

7. Global Bone Cancer Drugs Market, By Region, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Segment Trends
North America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 -2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Advaxis, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Cellectar Biosciences, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- OPKO Health, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Amgen Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eli Lilly and Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Debiopharm Group
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Merck & Co.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bayer AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bristol-Myers Squibb Company
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Takeda Pharmaceutical
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Hoffmann-La Roche Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Teva Pharmaceutical
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Analyst Views

9. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

骨癌药物市场：依药物类型、适应症、通路和地区划分

Bone Cancer Drugs Market, By Drug Type, By Disease Indication, By Distribution Channel, and By Region

市场动态

目录

第一章研究目的与前提

第二章市场展望

第三章：市场动态、法规与趋势分析

4. 2020-2032 年全球骨癌药物市场（依药物类型）

5. 全球骨癌药物市场（依适应症划分），2020-2032 年

6. 2020-2032 年全球骨癌药物市场（按分销管道）

7. 2020-2032 年全球骨癌药物市场（按地区）

第八章竞争态势

第九章章节